Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7415217rdf:typepubmed:Citationlld:pubmed
pubmed-article:7415217lifeskim:mentionsumls-concept:C0043335lld:lifeskim
pubmed-article:7415217lifeskim:mentionsumls-concept:C1157337lld:lifeskim
pubmed-article:7415217pubmed:issue5lld:pubmed
pubmed-article:7415217pubmed:dateCreated1980-11-20lld:pubmed
pubmed-article:7415217pubmed:abstractText1. When 3-phenoxy[14C]benzoic acid was dosed orally (0.76 mg/kg) to rats, 1--3% of the administered radioactivity was found in the skin four days after dosing. Approximately 90% of this residue was unchanged 3-phenoxybenzoate, 10% was a neutral compound. 2. The residue in the skins of rats dosed with 193 mg of 3-phenoxybenzoic acid over 7 days (c. 100 mg/kg per day) contained 40% 3-phenoxybenzoate and 60% neutral metabolites. 3. The components were separated and purified by gel permeation, absorption and t.l.c. and analysed by mass spectrometry. 4. 2- and 3-(3-Phenoxybenzoyl)dipalmitins were major components of the neutral metabolite.lld:pubmed
pubmed-article:7415217pubmed:languageenglld:pubmed
pubmed-article:7415217pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7415217pubmed:citationSubsetIMlld:pubmed
pubmed-article:7415217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7415217pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7415217pubmed:statusMEDLINElld:pubmed
pubmed-article:7415217pubmed:monthMaylld:pubmed
pubmed-article:7415217pubmed:issn0049-8254lld:pubmed
pubmed-article:7415217pubmed:authorpubmed-author:HutsonD HDHlld:pubmed
pubmed-article:7415217pubmed:authorpubmed-author:CrayfordJ VJVlld:pubmed
pubmed-article:7415217pubmed:issnTypePrintlld:pubmed
pubmed-article:7415217pubmed:volume10lld:pubmed
pubmed-article:7415217pubmed:ownerNLMlld:pubmed
pubmed-article:7415217pubmed:authorsCompleteYlld:pubmed
pubmed-article:7415217pubmed:pagination349-54lld:pubmed
pubmed-article:7415217pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:meshHeadingpubmed-meshheading:7415217-...lld:pubmed
pubmed-article:7415217pubmed:year1980lld:pubmed
pubmed-article:7415217pubmed:articleTitleXenobiotic triglyceride formation.lld:pubmed
pubmed-article:7415217pubmed:publicationTypeJournal Articlelld:pubmed